Importance of Zinc Transporter 8 Autoantibody in the Diagnosis of Type 1 Diabetes in Latin Americans

Mostrar registro simples

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP GOMES, Karla Fabiana Brasil FMUSP-HC
FUKUI, Rosa Tsuneshiro FMUSP-HC
SANTOS, Aritania Sousa FMUSP-HC
SILVA, Maria Elizabeth Rossi da FMUSP-HC 2017
dc.description.abstract There is a scarcity of data of zinc transporter-8 autoantibody (ZnT8A) on mixed populations such as Brazilian. Therefore, we evaluated the relevance of ZnT8A for type 1 diabetes (T1D) diagnosis and the role of ZnT8 coding gene (SLC30A8) in T1D predisposition. Patients with T1D (n=629; diabetes duration = 11 (6-16) years) and 651 controls were genotyped for SLC30A8 rs16889462 and rs2466295 variants (BeadXpress platform). ZnT8 triple antibody was measured by ELISA; glutamic acid decarboxylase (GAD65A) and protein tyrosine phosphatase (IA-2A) autoantibodies by radioimmunoassay. Results: Znt8A was detected in 68.7% of recent-onset T1D patients and 48.9% of the entire patient cohort, similar to GAD65A (68.3% and 47.2%) and IA-2A (64.8% and 42.4%) positivities respectively. ZnT8A was the only antibody in 8.4% of patients. Znt8A and IA2A frequencies and titers were independent of gender and ethnicity, whereas GAD65A titers were greater in females. The diabetes duration-dependent decline in ZnT8A frequency was similar to GAD65A and IA-2A. The SLC30A8 rs2466293 AG + GG genotypes were associated with T1D risk in non-European descents (56.2% x 42.9%; p=0.018), and the GG genotype with higher ZnT8A titers in recent-onset T1D: 834.5 IU/mL (711.3-2190.0) x 281 IU/mL (10.7-726.8); p=0.027. Conclusion ZnT8A detection increases T1D diagnosis rate even in mixed populations. SLC30A8 rs2466293 was associated with T1D predisposition in non-European descents. LIM/18
dc.description.index MEDLINE
dc.description.sponsorship · Sao Paulo Research Foundation (FAPESP)
dc.identifier.citation SCIENTIFIC REPORTS, v.7, article ID 207, 7p, 2017
dc.identifier.doi 10.1038/s41598-017-00307-4
dc.identifier.issn 2045-2322
dc.identifier.pmid 28303020
dc.language.iso eng
dc.relation.ispartof Scientific Reports
dc.rights openAccess
dc.rights.holder Copyright NATURE PUBLISHING GROUP
dc.subject.other slc30a8 gene; association; onset; children; mellitus; chinese; polymorphism; progression; variants; decline
dc.title Importance of Zinc Transporter 8 Autoantibody in the Diagnosis of Type 1 Diabetes in Latin Americans
dc.type article
dc.type.category original article
dc.type.version publishedVersion GOMES, Karla Fabiana Brasil:FM: SEMZEZEM, Cintia:FM: BATISTA, Rodolfo:HC:LIM/18 FUKUI, Rosa Tsuneshiro:FM:MCM SANTOS, Aritania Sousa:HC:ICHC CORREIA, Marcia Regina:HC:LIM/18 SILVA, Maria Elizabeth Rossi da:HC:ICHC · PASSOS-BUENO, Maria Rita:Univ Sao Paulo, Inst Biociencias, Dept Genet & Biol Evolut, Rua Matao 277, BR-05422970 Sao Paulo, SP, Brazil WOS:000404126200006 LONDON ENGLAND
hcfmusp.relation.reference · Achenbach P, 2009, DIABETOLOGIA, V52, P1881, DOI 10.1007/s00125-009-1438-0
· American Diabetes Association Classification and diagnosis of diabetes, 2015, DIABETES CARE S1, V38, pS8, DOI 10.2337/DC15-S005
· Andersson C, 2011, AUTOIMMUNITY, V44, P394, DOI 10.3109/08916934.2010.540604
· Andersson C., 2011, PEDIAT DIABETES, V14, P97
· Billings LK, 2014, J CLIN ENDOCR METAB, V99, pE926, DOI 10.1210/jc.2013-2378
· Mattana TCC, 2014, MEDIAT INFLAMM, DOI 10.1155/2014/694948
· de Souza ACCB, 2015, HEALTH QUAL LIFE OUT, V13, DOI 10.1186/s12955-015-0396-0
· Delli AJ, 2012, DIABETES, V61, P2556, DOI 10.2337/db11-1659
· Eisenbarth G. S., 2015, TYPE 1 DIABETES CELL
· Goda N, 2015, BMC MED GENET, V16, DOI 10.1186/s12881-015-0219-5
· Gohlke Henning, 2008, Rev Diabet Stud, V5, P25, DOI 10.1900/RDS.2008.5.25
· Herold KC, 2009, CLIN IMMUNOL, V132, P166, DOI 10.1016/j.clim.2009.04.007
· Huang QO, 2010, EUR J CLIN PHARMACOL, V66, P1207, DOI 10.1007/s00228-010-0882-6
· Kawasaki E, 2011, CLIN IMMUNOL, V138, P146, DOI 10.1016/j.clim.2010.10.007
· Miller S. A., 1998, NUCLEIC ACIDS RES, V16, P215, DOI 10.1093/NAR/16.3.1215
· Naserke HE, 1998, J IMMUNOL, V161, P6963
· Nielsen LB, 2011, AUTOIMMUNITY, V44, P616, DOI 10.3109/08916934.2011.576724
· Pena SDJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017063
· Raj SM, 2009, DIABETOLOGIA, V52, P2109, DOI 10.1007/s00125-009-1391-y
· Salonen KM, 2013, DIABETES-METAB RES, V29, P646, DOI 10.1002/dmrr.2440
· Sladek R, 2007, NATURE, V445, P881, DOI 10.1038/nature05616
· Vaziri-Sani F, 2011, J IMMUNOL METHODS, V371, P25, DOI 10.1016/j.jim.2011.06.011
· Vaziri-Sani F, 2010, AUTOIMMUNITY, V43, P598, DOI 10.3109/08916930903555927
· Wenzlau JM, 2010, J CLIN ENDOCR METAB, V95, P4712, DOI 10.1210/jc.2010-0169
· Wenzlau JM, 2008, DIABETES, V57, P2693, DOI 10.2337/db08-0522
· Wenzlau JM, 2007, P NATL ACAD SCI USA, V104, P17040, DOI 10.1073/pnas.0705894104
· Wenzlau JM, 2015, DIABETES CARE, V38, pS14, DOI 10.2337/dcs15-2004
· Wenzlau JM, 2008, ANN NY ACAD SCI, V1150, P256, DOI 10.1196/annals.1447.029
· Wijesekara N, 2010, DIABETOLOGIA, V53, P1656, DOI 10.1007/s00125-010-1733-9
· Yang L, 2010, DIABETES-METAB RES, V26, P579, DOI 10.1002/dmrr.1128
· Zhang Y, 2015, DIABETES-METAB RES, V31, P790, DOI 10.1002/dmrr.2670
hcfmusp.source 2-s2.0-85033788529

Arquivos deste item

Este item aparece na(s) seguinte(s) coleção(s)

Mostrar registro simples

Buscar no OPI


Minha conta